The patients exhibited significantly lower levels of key apolipoproteins, including apoA-1, apoA-2, apoC-2, and apoC-4, compared to luminal A, luminal B, and HER2-positive breast cancer patients (p-values ranging from 0.004 to 0.057). This evidence concerns the gene ERBB2 and breast carcinoma.